Fate Therapeutics (FATE) Tops Q1 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $876 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Popular stocks with increasing option volume: SPCX NFLX INTC PLTR META SMCI MU SOFI NOK MSTR AVGO HOOD
• Tradr 2X Long SpaceX Daily ETF (SPCM) call put ratio 6.8 calls to 1 put with a focus on July 28 calls as share price down 20.6%